Skip to main content

Table 3 Patient populations & clinical measures

From: An open-label pilot trial of minocycline in children as a treatment for Angelman syndrome

Participant Sex Age (Months) Daily dosage (mg) CGI EEG
T1 T2 T3 T1 T2 T3
1 Female 100 200 5 4 5 4 7 4
2 Male 88 100 4 4 4 8 9 6
3 Female 124 200 7 6 7 11 7 12
4 Female 128 200 6 5 5 14 12 11
5 Male 119 100 4 4 3 5 5 3
6 Male 160 200 5 4 5 6 6 6
7 Female 89 100 5 5 5 5 9 5
8 Female 101 200 5 5 5 8 5 9
9 Male 60 100 6 5 6 15 9 12
10 Male 86 200 4 4 4 8 8 6
11 Female 89 100 5 5 5 12 9 8
12 Female 112 200 4 3 3 9 8 5
13 Female 111 100 6 4 4 9 9 6
14 Male 76 200 6 6 6 9 9 8
15 Male 127 200 6 5 6 6 6 4
16 Male 63 100 7 6 6 14 11 16
17 Female 72 100 5 4 5 14 12 12
18 Female 83 100 5 4 3 9 9 9
19 Male 97 100 5 4 4 5 7 11
20 Male 125 200 5 5 5 10 15 3
21 Male 130 200 7 7 7 10 9 10
22 Male 148 200 8 7 7 4 3 8
23 Male 120 200 5 5 5 14 13 13
24 Male 87 100 7 7 - 7 9 -
25 Female 85 100 7 6 7 13 13 9
  Mean ± Standard Deviation 5.56 ± 1.12 *4.96 ± 1.10 *5.08 ± 1.25 9.16 ± 3.47 8.76 ± 2.80 8.16 ± 3.47
  Standard Error of the Mean 0.224 0.220 0.255 0.694 0.561 0.709
  η 2   0.05    0.05  
  1. η2 (Partial Eta squared) is a measure of effect size. 0.01 suggests a small effect, 0.06 a medium effect and 0.14 a large effect.
  2. *Indicates p < 0.05 when the time point is compared to T1 (baseline).